Skip to main content

Pregabalin

NDC 71610-754 · Aphena Pharma Solutions - Tennessee, LLC

Generic namePREGABALIN
Dosage formCAPSULE
RouteORAL
Active ingredient(s)PREGABALIN
Strength200 mg/1
DEA scheduleCV
Marketing categoryANDA

Packages

71610-754-30 — 30 CAPSULE in 1 BOTTLE (71610-754-30)

71610-754-46 — 56 CAPSULE in 1 BOTTLE (71610-754-46)

71610-754-53 — 60 CAPSULE in 1 BOTTLE (71610-754-53)

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

71610-314 — PREGABALIN, 71610-316 — PREGABALIN, 71610-317 — PREGABALIN, 71610-318 — PREGABALIN, 71610-319 — PREGABALIN, 71610-320 — PREGABALIN, 71610-618 — PREGABALIN, 71610-619 — PREGABALIN, 71610-677 — PREGABALIN, 71610-719 — Pregabalin, 71610-758 — Pregabalin, 71610-759 — Pregabalin, 71610-760 — Pregabalin, 71610-765 — PREGABALIN, 71610-792 — Pregabalin, 71610-799 — Pregabalin, 71610-800 — PREGABALIN, 71610-808 — Pregabalin, 71610-820 — Pregabalin, 71610-845 — Pregabalin, +519 more

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels